An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms DB in 3L MBC
- Sponsors GlaxoSmithKline; Novartis
- 29 Aug 2019 Planned End Date changed from 4 Sep 2019 to 4 Dec 2019.
- 29 Aug 2019 Planned primary completion date changed from 5 May 2019 to 4 Dec 2019.
- 19 Jun 2019 Planned End Date changed from 3 Jun 2019 to 4 Sep 2019.